EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From mRNA Vaccines to In Vivo CAR-T Therapy: RNA-LNP Design and the Pharmacology of CAR-Positive Cells

Yixin Wang, Lei Yu, Xingquan Ma, Li Ma, Yongjun Yang, Sheng Li, Xiaoyong Li, Yuanyuan Fu, Fujie Cui, Gao Meng, Bin Zheng, Zhi Huang und 4 weitere

Vaccines · 31.10.2026 · 14 (11) · 951

DOI: 10.3390/vaccines14110951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 31.10.2026. Verfasst von Yixin Wang und 15 weiteren Autor:innen. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA vaccines established scalable manufacturing and lipid nanoparticle (LNP) delivery for sequence-defined, non-integrating RNA medicines. In vivo CAR-T therapy repurposes this platform to generate CAR-positive lymphocytes after intravenous dosing, but its active product is a time-varying cell population rather than the injected RNA mass. This review critically examines the pharmacological sequence from biodistribution and cell-specific uptake to cytosolic RNA release, surface CAR expression, effector function, and disease response. The evidence comprises primary human T cells, mice, humanized mice, non-human primates, and 11 patients described in one correspondence and two meeting abstracts (as of July 2026). Matched studies show that receptor internalization can outweigh surface abundance, ligand density follows a non-monotonic relationship with delivery, and lipid chemistry and ligand presentation independently alter productive T-cell transfection. Preclinical models demonstrate transient CAR expression and target-cell depletion, whereas current human reports establish feasibility but not durable efficacy, a dose–response relationship, or the incidence of uncommon toxicities. We therefore distinguish administered dose, cell-resolved CAR-positive-cell exposure, and pharmacodynamic response, and propose their joint measurement as the basis for comparing platforms and selecting repeat-dose regimens.

Förderung

  • Zhejiang Provincial Natural Science Foundation

Zitieren

APA

Wang, Y., Yu, L., Ma, X., Ma, L., Yang, Y., Li, S., Li, X., Fu, Y., Cui, F., Meng, G., Zheng, B., Huang, Z., Liu, Y., Dong, X., Xiong, C., & Wang, Y. (2026). From mRNA Vaccines to In Vivo CAR-T Therapy: RNA-LNP Design and the Pharmacology of CAR-Positive Cells. Vaccines, 14(11), 951. https://doi.org/10.3390/vaccines14110951

Vancouver

Wang Y, Yu L, Ma X, Ma L, Yang Y, Li S, et al. From mRNA Vaccines to In Vivo CAR-T Therapy: RNA-LNP Design and the Pharmacology of CAR-Positive Cells. Vaccines. 2026;14(11):951. doi:10.3390/vaccines14110951

BibTeX
@article{Wang2026,
  author = {Wang, Yixin and Yu, Lei and Ma, Xingquan and Ma, Li and Yang, Yongjun and Li, Sheng and Li, Xiaoyong and Fu, Yuanyuan and Cui, Fujie and Meng, Gao and Zheng, Bin and Huang, Zhi and Liu, Yang and Dong, Xingxing and Xiong, Changyun and Wang, Youru},
  title = {From mRNA Vaccines to In Vivo CAR-T Therapy: RNA-LNP Design and the Pharmacology of CAR-Positive Cells},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {11},
  pages = {951},
  doi = {10.3390/vaccines14110951}
}
Kostenlos starten →